Korea develops AI-based microneedle patch for diabetic wound healing

Singapore, June 26 -- Chronic diabetic wounds heal slowly and are highly vulnerable to infection. Addressing this concern, researchers at Hanyang University, South Korea, have developed an artificial ... Read More

CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand

Singapore, June 26 -- CStone Pharmaceuticals, a China-based biopharmaceutical company, has entered into an exclusive commercialisation agreement with Arrotex Pharmaceuticals, a core pharmaceutical com... Read More

Mubadala Bio partners with Biosidus to advance access to biologic therapies in UAE

Singapore, June 26 -- Mubadala Bio has announced the signing of a licencing and supply agreement with Biosidus, a leading biotechnology company in Argentina, at the BIO International Convention 2026 i... Read More

Australia announces $11 M grant to boost Autism research

Singapore, June 25 -- La Trobe University's Olga Tennison Autism Research Centre will receive $11.1 million over three years to establish the Australian Autism Knowledge Hub, as part of the Australian... Read More

Abu Dhabi announces partnership with MSD to advance healthcare operational excellence

Singapore, June 25 -- As healthcare systems worldwide seek more resilient and efficient pathways to deliver innovative medicines, the Department of Health - Abu Dhabi (DoH) has announced a collaborati... Read More

ATLATL and Samsung Bioepis to accelerate early-stage biotech innovation across Asia-Pacific

Singapore, June 25 -- China-based ATLATL Innovation Center, a global innovation platform for life science research and development, and Korea's Samsung Bioepis have announced the launch of the Samsung... Read More

Where Asia Builds the Future of Care

Singapore, June 25 -- Healthcare systems across Southeast Asia are navigating a period of unprecedented change. Ageing populations, rising healthcare demands, workforce constraints and rapid technolog... Read More

Ollin raises $330M to advance Phase III retinal disease programme

Singapore, June 25 -- Ollin Biosciences has completed an oversubscribed US$330 million Series B financing to advance global Phase III development of OLN324, also known as IBI324, in retinal vascular d... Read More

CeleCor submits FDA application for investigational heart attack drug

Singapore, June 25 -- CeleCor Therapeutics has completed submission of its New Drug Application to the U.S. FDA for zalunfiban, its investigational heart attack drug. The filing follows positive Phas... Read More

First PMDA-approved molecular residual disease (MRD) test enters Japan

Singapore, June 24 -- US-based Natera, Inc., a global leader in cell-free DNA and precision medicine, has announced that Signatera has received regulatory approval from Japan's Pharmaceuticals and Med... Read More

• «
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• »
• »»